Plasma pentraxin-3 is associated with endothelial dysfunction in non-alcoholic fatty liver disease

Gurel H., Genc H., Celebi G., Sertoglu E., Cicek A. F., KAYADİBİ H., ...Daha Fazla

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, cilt.20, sa.20, ss.4305-4312, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 20
  • Basım Tarihi: 2016
  • Dergi Adı: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.4305-4312
  • Anahtar Kelimeler: Pentraxin-3, Endothelial dysfunction, Non-alcoholic fatty liver disease, HOMEOSTASIS MODEL ASSESSMENT, C-REACTIVE PROTEIN, STEATOHEPATITIS NASH, CARDIOVASCULAR RISK, OBESITY, SENSITIVITY, ACTIVATION, SEVERITY, GLUCOSE, PTX3
  • Eskişehir Osmangazi Üniversitesi Adresli: Hayır

Özet

OBJECTIVE: Pentraxin-3 (PTX3) is an acute-phase protein belonging to the PTX family. It has been reported that PTX-3 is significantly associated with obesity, metabolic syndrome, and cardiovascular diseases (CVD). Non-alcoholic fatty liver disease (NAFLD) is strongly associated with atherosclerosis and CVD. In this study, we aimed to investigate the relationship of PTX-3 with circulating markers of endothelial dysfunction and atherosclerosis in patients with NAFLD.